Free Trial
Notice: Trading of Lexicon Pharmaceuticals halted at 06:55 AM EST due to "News pending".
NASDAQ:LXRX

Lexicon Pharmaceuticals (LXRX) Stock Price, News & Analysis

Lexicon Pharmaceuticals logo
$1.95
-0.08 (-3.94%)
(As of 10/30/2024 ET)

About Lexicon Pharmaceuticals Stock (NASDAQ:LXRX)

Key Stats

Today's Range
$1.92
$2.08
50-Day Range
$1.51
$2.08
52-Week Range
$0.92
$3.73
Volume
6.46 million shs
Average Volume
3.39 million shs
Market Capitalization
$480.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00
Consensus Rating
Moderate Buy

Company Overview

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

Lexicon Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
38th Percentile Overall Score

LXRX MarketRank™: 

Lexicon Pharmaceuticals scored higher than 38% of companies evaluated by MarketBeat, and ranked 779th out of 993 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lexicon Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Lexicon Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.

  • Read more about Lexicon Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Lexicon Pharmaceuticals are expected to grow in the coming year, from ($0.69) to ($0.63) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lexicon Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lexicon Pharmaceuticals is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lexicon Pharmaceuticals has a P/B Ratio of 5.13. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lexicon Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    11.23% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lexicon Pharmaceuticals has recently increased by 2.52%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lexicon Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Lexicon Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    11.23% of the outstanding shares of Lexicon Pharmaceuticals have been sold short.
  • Short Interest Ratio / Days to Cover

    Lexicon Pharmaceuticals has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lexicon Pharmaceuticals has recently increased by 2.52%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Lexicon Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Lexicon Pharmaceuticals this week, compared to 3 articles on an average week.
  • Search Interest

    8 people have searched for LXRX on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Lexicon Pharmaceuticals to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lexicon Pharmaceuticals insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 6.80% of the stock of Lexicon Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    74.70% of the stock of Lexicon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lexicon Pharmaceuticals' insider trading history.
Receive LXRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lexicon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

LXRX Stock News Headlines

This man believes TSLA will reach $500 a share…
Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.
Lexicon announces new analysis of Phase 3 SCORED trial
Lexicon’s LX9211 progressing ahead of schedule, says H.C. Wainwright
Lexicon completes screening in Phase 2B progress study of LX9211
See More Headlines

LXRX Stock Analysis - Frequently Asked Questions

Lexicon Pharmaceuticals' stock was trading at $1.53 at the beginning of the year. Since then, LXRX stock has increased by 27.5% and is now trading at $1.95.
View the best growth stocks for 2024 here
.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) released its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.01. The biopharmaceutical company earned $1.65 million during the quarter, compared to analysts' expectations of $2.74 million. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative trailing twelve-month return on equity of 105.38%.

Lexicon Pharmaceuticals' top institutional shareholders include Pinnacle Associates Ltd. (0.70%), Hennion & Walsh Asset Management Inc. (0.30%), Compagnie Lombard Odier SCmA (0.04%) and China Universal Asset Management Co. Ltd. (0.03%). Insiders that own company stock include International SCA Artal, Raymond Debbane, Lonnel Coats, Jeffrey L Wade and Wendy Mcdermott.
View institutional ownership trends
.

Shares of LXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lexicon Pharmaceuticals investors own include Portola Pharmaceuticals (PTLA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), Netflix (NFLX) and Moderna (MRNA).

Company Calendar

Last Earnings
8/01/2024
Today
10/31/2024
Next Earnings (Estimated)
11/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:LXRX
Previous Symbol
NASDAQ:LEXG
CUSIP
52887210
Employees
285
Year Founded
1995

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+310.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-177,120,000.00
Net Margins
-5,509.34%
Pretax Margin
-5,550.87%

Debt

Sales & Book Value

Annual Sales
$3.64 million
Book Value
$0.38 per share

Miscellaneous

Free Float
229,493,000
Market Cap
$480.16 million
Optionable
Optionable
Beta
1.28

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

This page (NASDAQ:LXRX) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners